C&L: Berendt tapped to run Aegera

Aegera Therapeutics has appointed Dr. Michael J. Berendt as the company's president and CEO. 

Ablynx Chairman Dr Edwin Moses has accepted the board's offer to extend his role to include that of CEO. 

Quintiles Transnational has appointed Yoh Narimatsu president and CEO of Quintiles Transnational Japan.

Clinquest has hired Eugene C. Poggio, PhD, as president and chief biostatistician.

Biosystems Informatics Institute has hired Colin Proudfoot as CFO.

Avigen announced that Dawn McGuire M.D. will be resigning as chief medical officer effective April 12, 2006 for personal health reasons. Drew Jones M.D. has been appointed senior director of clinical affairs and Michael Hensley M.D. will serve as head of Avigen Regulatory Affairs.

Charles River Laboratories International has named Nicholas Ventresca corporate senior vice president, information technology and chief information officer.

Dendreon Corporation has named Christopher Lockett senior director of government affairs.

AtheroGenics announced that Walker Anderson Long, M.D. has joined the company as vice president of clinical research.

Ruthann DePietro has joined Insulet Corporation as vice president of quality and regulatory affairs.

Nuvelo has named Shelly D. Guyer as vice president, business development and investor relations.

John G. Cox has been promoted to run Biogen Idec's Research Triangle Park operation.

Michael Brawer, M.D. has been named Urology Therapeutic Area Head for Threshold Pharmaceuticals.

Steven R. Altman has been elected to Amylin Pharmaceuticals' board of directors.

Corgenix Medical has named Charles H. Scoggin, M.D. and Larry G. Rau directors of the company.

SCYNEXIS has selected Dr. Pamela Kirby as the new chairman of the company's board of directors, replacing Philip Chauveau, who is retiring as board chairman but will remain as a board member.

Donald McCaffrey, president and CEO of Resverlogix Corp., has resigned from Stem Cell Therapeutics' board of directors.

Science Foundation Arizona has named William C. Harris, Ph.D., president and chief executive.

Altus Pharmaceuticals announced that Harry H. Penner, Jr., co-founder, chairman and chief executive of Marinus Pharmaceuticals, has been appointed to the Altus board of directors.

Suggested Articles

Out of options, Tocagen will become Forte Biosciences’ route to the public markets through an all-stock reverse merger.

Reich co-founded Effector and served as its SVP of research but has moved on to take up the CSO position at Turning Point Therapeutics.

BioMarin’s hemophilia A drug has been set an Aug. 21 PDUFA date as the California biotech looks to gain a speedy approval.